Skip to main content
. 2016 May 10;5:e14137. doi: 10.7554/eLife.14137

Figure 1. Effects of COX-2 inhibition in the NIH assay.

Effects of vehicle, LM-4131, Lumiracoxib, and Celecoxib administered 2 hr prior to behavioral testing on feeding latency under non-stressed (control conditions) (A), and 4 hr (B), 8 hr (C), 24 hr (D), and 72 hr (E) after foot-shock stress (experimental design shown above). Cumulative distribution curves depict percentage of mice feeding at each latency time point (sec), while bar graphs represent mean ± S.E.M feeding latency for each group and individual data points. Each point represents 1 mouse. (F) Re-plotted data from A-E in time-course format depicting effects of drugs on feeding latency over time. Significant F and P values from one-way ANOVA noted above bar graphs; *p<0.05, **p<0.01, ****p<0.0001 by Holm-Sidak post hoc multiple comparisons test in bar graphs. For cumulative frequency distributions, *p<0.05, ****p<0.0001 by K-S test.

DOI: http://dx.doi.org/10.7554/eLife.14137.003

Figure 1.

Figure 1—figure supplement 1. Effects of COX-2 inhibition on feeding latency in the NIH assay in 4-month-old male mice.

Figure 1—figure supplement 1.

(A) Effects of LM-4131 and Lumiracoxib (LMX) on feeding latency in control, non-stressed mice. (B) Effects of LM-4131, LMX, and Celecoxib on feeding latency tested 8 hr after acute foot-shock exposure. Significant F and P values for one-way ANOVA shown above figures. **p<0.01 by Holm-Sidak post hoc multiple comparisons test. For cumulative distribution curves, **p<0.01, ****p<0.0001 by K-S test.
DOI: http://dx.doi.org/10.7554/eLife.14137.004
Figure 1—figure supplement 2. Effects of COX-2 inhibition on feeding latency in the NIH test in female mice.

Figure 1—figure supplement 2.

(A) Effects of LM-4131 on feeding latency in the NIH assay under control, non-stressed conditions in female mice. (B) Effects of LM-4131 on feeding latency 8 hr after foot-shock exposure. (C) Effects of Rimonabant + vehicle, or Rimonabant + LM-4131 co-treatment, on feeding latency tested 8 hr after foot-shock exposure. *p<0.05 by two-tailed unaired t-test. For cumulative distribution curves, **p<0.01 by K-S test.
DOI: http://dx.doi.org/10.7554/eLife.14137.005
Figure 1—figure supplement 3. Effects of COX-2 inhibition on feeding latency in the NIH test after sub-chronic stress.

Figure 1—figure supplement 3.

(A) Effects of LM-4131 and Lumiracoxib (LMX) on feeding latency in the NIH assay under control, non-stressed conditions. (B) Effects of LM-4131 and LMX on feeding latency in the NIH assay 8 hr after the last of 5 daily foot-shock exposures. Significant F and P values by one-way ANOVA shown above figures. **p<0.01 by Holm-Sidak post hoc multiple comparisons test. For cumulative distribution curves, ****p<0.0001 by K-S test.
DOI: http://dx.doi.org/10.7554/eLife.14137.006
Figure 1—figure supplement 4. Effects of subchronic COX-2 inhibition on feeding latency in the NIH test.

Figure 1—figure supplement 4.

(A) Effects of 5 consecutive daily administrations of Lumiracoxib (LMX) on feeding latency and food consumption in the NIH test, and body weight, in control non-stressed mice. (B) Effects of 5 consecutive daily administrations of LMX on feeding latency and food consumption in the NIH test 8 hr after foot-shock exposure. *p<0.05 by two-tailed unpaired t-test. For cumulative distribution curves, ****p<0.0001 by K-S test.
DOI: http://dx.doi.org/10.7554/eLife.14137.007
Figure 1—figure supplement 5. Effects of COX-2 inhibition on locomotor activity in the open field test.

Figure 1—figure supplement 5.

(A) Effects of LM-4131 on total distance travelled. (B) Effects of Lumiracoxib on total distance travelled.
DOI: http://dx.doi.org/10.7554/eLife.14137.008